A composition comprising a main species HER2 antibody that binds to domain
II of HER2, and an amino acid sequence variant thereof comprising an
amino-terminal leader extension is disclosed. Pharmaceutical formulations
comprising the composition, and therapeutic uses for the composition are
also disclosed.